Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivoglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 12/20 | 1.00 |
| ▸ | ESRRA | P11474 | 1/20 | 0.73 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.63 |
| ▸ | PPARA | Q07869 | 6/20 | 0.63 |
| ▸ | MPC2 | O95563 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivoglitazone SCHEMBL5319250 | 1.00 | PPARG (1.00) | PPARGESRRAFFAR1PPARAMPC2 | |
| Rivoglitazone SCHEMBL2906120 | 1.00 | PPARG (1.00) | PPARGESRRAFFAR1PPARAMPC2 | |
| Rivoglitazone SCHEMBL1592290 | 0.99 | PPARG (0.98) | PPARGESRRAFFAR1PPARAMPC2 | |
| Rivoglitazone SCHEMBL6064788 | 0.99 | PPARG (0.98) | PPARGESRRAFFAR1PPARAMPC2 | |
| Rivoglitazone SCHEMBL4885815 | 0.96 | PPARG (0.91) | PPARGESRRAFFAR1PPARAMPC2 | |
| SCHEMBL6543624 | 0.95 | PPARG (0.90) | PPARGESRRAFFAR1PPARAMPC2 | |
| Hydrochloric Acid SCHEMBL6544473 | 0.94 | PPARG (0.88) | PPARGESRRAFFAR1PPARAMPC2 | |
| SCHEMBL15730390 | 0.94 | PPARG (0.88) | PPARGESRRAFFAR1PPARAMPC2 | |
| SCHEMBL6896700 | 0.93 | PPARG (0.86) | PPARGESRRAFFAR1PPARAMPC2 | |
| SCHEMBL14168935 | 0.92 | PPARG (0.84) | PPARGESRRAFFAR1PPARAMPC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1900 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360215-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | YUH CHIOU HWA (US) | 2025-11-27 | — | — | US | claimed |
| US-20250332101-A1 | Composition | CORDEIRO MARIA FRANCESCA (GB) | 2025-10-30 | — | — | US | claimed |
| EP-4640701-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-10-29 | — | — | EP | claimed |
| US-20250281507-A1 | METHODS OF TREATING NEPHROTIC SYNDROME | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL | 2025-09-11 | — | — | US | claimed |
| US-20250221962-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD (IL) | 2025-07-10 | — | — | US | claimed |
| WO-2025136060-A1 | CULTURE MEDIUM COMPOSITION FOR TRANSDIFFERENTIATION OF MUSCLE STEM CELLS INTO ADIPOCYTES, AND METHOD FOR PRODUCING CULTURED MEAT BY USING SAME | 한화솔루션 주식회사 | 2025-06-26 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250082781-A1 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2025-03-13 | — | — | US | claimed |
| EP-4520343-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-03-12 | — | — | EP | claimed |
| WO-2025049710-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE DISEASE TREATMENTS | ACLIPSE TWO INC. (US) | 2025-03-06 | — | — | WO | claimed |
| EP-0796618-B1 | Treatment and prophylaxis of pancreatitis | SANKYO CO (JP) | 2002-01-30 | — | — | EP | claimed |
| EP-0753298-B1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO CO (JP) | 2001-11-21 | — | — | EP | claimed |
| EP-0745600-B1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | claimed |
| US-6159997-A | Treatment of arteriosclerosis and xanthoma | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | claimed |
| US-6150371-A | WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 2000-11-21 | — | — | US | claimed |
| WO-2000041690-A1 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-20 | — | — | WO | claimed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | claimed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | claimed |
| EP-0753298-A1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO COMPANY LIMITED (JP) | 1997-01-15 | — | — | EP | claimed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082781-A1 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | PDE4D, PDE4A, PDE4B | PPARG 129/4885ESRRA 1192/4885FFAR1 1346/4885 |
| US-20250281507-A1 | METHODS OF TREATING NEPHROTIC SYNDROME | PPARA, PPARG, PPARD | PPARG 2/4885ESRRA 217/4885FFAR1 131/4885 |
| US-20250221962-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | FABP4, FABP2, FABP1 | PPARG 46/4885ESRRA 3040/4885FFAR1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.